ARCHIVES

FDA, NCI Remain At Odds Over Drug approval Guidelines Despite Reconciliation Discussion

This article is from The Cancer Letter archive.

Vol. 13 No. 39 | October 9, 1987

Download PDF Visit The Full Archive

Related Articles

Gleevec Approval Sets Record For FDA Review: 73 Days

May 25, 2001

In congress: Sen. Harkin: “What Causes Cancer” If We Don’t Know The Cause, How Can We Get Into Prevention?

June 27, 1997

Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease

November 30, 2012

VEGF Levels Can Predict Tumor’s Resistance to Avastin

July 29, 2011

NCAB Supports ACS Effort To Work With Centers

March 1, 1991

CCI Gets Qualified Approval To Continue

January 18, 1980